Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
D-Lys6 gonadotropin-releasing hormone is a synthetic peptide analog of the naturally occurring gonadotropin-releasing hormone (GnRH), also known as luteinizing hormone-releasing hormone (LHRH). It functions as a potent agonist of the GnRH receptor, primarily located on gonadotrope cells in the pituitary gland. Upon binding, it initially stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, continuous exposure leads to desensitization and downregulation of the GnRH receptors, ultimately suppressing gonadotropin and sex hormone production. This mechanism makes it a valuable research tool for exploring reproductive physiology and investigating hormone-dependent conditions such as prostate, breast, and ovarian cancers, as well as various gynecological disorders and precocious puberty. While primarily designed for biological research and industrial applications, its action is analogous to clinically used GnRH agonists.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on D-Lys6 gonadotropin-releasing hormone.